Ventripoint Diagnostics Announces Private Placement of Units

Toronto, Ontario — December 30, 2025 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV:VPT) has announced a non-brokered private placement to raise up to $500,000.

The offering will consist of up to 5,000,000 units, priced at $0.10 per unit, subject to TSXV Venture Exchange acceptance. Each unit includes one common share of the Corporation and one common share purchase warrant.

Each whole warrant allows the holder to purchase one common share at $0.13 for 24 months from the offering's closing. The Corporation can accelerate the warrant expiry with 30 days' notice if common shares trade at $0.26 for 10 consecutive days, even if no trades occur on some of those days.

The Corporation may pay a cash finder’s fee and issue common share purchase warrants of up to 8% of the gross proceeds. Each Finder’s Warrant can be exercised into one common share at CDN$0.13 per share for 24 months from the offering's closing.

The proceeds will fund operational costs for sales and marketing, additional key personnel, and general working capital.

All securities issued will be subject to a hold period of four months plus one day from the offering's closing. The offering is subject to Exchange approval.

The securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption.

Ventripoint Diagnostics Ltd. is described as an industry leader in applying AI to echocardiography. Its VMS+ products use knowledge-based reconstruction technology, providing cardiac measurements comparable to MRI. VMS+ is compatible with ultrasound systems from various vendors and has regulatory approvals in the U.S., Europe, and Canada.

Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Source: Ventripoint Diagnostics Ltd.